Pharvaris (NASDAQ:PHVS) President Peng Lu Sells 15,000 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) President Peng Lu sold 15,000 shares of the company’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $40.13, for a total transaction of $601,950.00. Following the sale, the president owned 65,179 shares of the company’s stock, valued at $2,615,633.27. This trade represents a 18.71% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Peng Lu also recently made the following trade(s):

• On Tuesday, September 8th, Peng Lu sold 15,000 shares of Pharvaris stock. The stock was sold at an average price of $40.68, for a total value of $610,200.00.
• On Thursday, June 18th, Peng Lu sold 300 shares of Pharvaris stock. The stock was sold at an average price of $34.00, for a total value of $10,200.00.

Pharvaris Stock Down 2.1%

Shares of NASDAQ:PHVS opened at $38.06 on Wednesday. The company has a market cap of $2.49 billion, a price-to-earnings ratio of -12.48 and a beta of -2.33. The business has a 50 day moving average price of $35.27 and a 200 day moving average price of $31.56. Pharvaris N.V. has a twelve month low of $20.65 and a twelve month high of $43.25.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). Analysts anticipate that Pharvaris N.V. will post -3.12 EPS for the current year.

Key Headlines Impacting Pharvaris

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris’ phase III data showed that once-daily extended-release deucrictibant reduced hereditary angioedema (HAE) attacks by 83%. The results support the company’s plans to pursue regulatory submissions in 2027 and strengthen the investment case for its lead drug candidate. PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
• Positive Sentiment: Analyst expectations have improved, with the consensus price target reportedly raised 20.08% to $59.77. Recent coverage also includes RBC raising its target to $62 and maintaining an outperform rating, while the broader analyst consensus remains “Moderate Buy.” Pharvaris NV consensus price target raised 20.08% to $59.77
• Positive Sentiment: Recent institutional buying—including new positions from BlackRock and increased holdings by Alyeska Investment Group and Seven Fleet Capital—signals growing professional-investor interest in PHVS.
• Neutral Sentiment: Pharvaris presented at the Morgan Stanley 24th Annual Global Healthcare Conference, giving management another opportunity to discuss deucrictibant and the company’s development and regulatory strategy with institutional investors. The supplied transcript headline does not identify a separate new announcement. Pharvaris Presents at Morgan Stanley Global Healthcare Conference
• Negative Sentiment: Insider selling is a counterweight: CEO Berndt Modig sold 2,291 shares, President Peng Lu sold 15,000 shares, and insider Anne Lesage sold 30,000 shares for approximately $1.15 million. Lu’s sale was specifically described as covering tax withholding tied to vested equity, which reduces—but does not eliminate—the negative signal. Insider Selling: Pharvaris Insider Sells 30,000 Shares

Analyst Upgrades and Downgrades

PHVS has been the subject of a number of research reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 price target on shares of Pharvaris in a report on Monday. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a report on Friday, July 17th. Royal Bank Of Canada upped their price objective on shares of Pharvaris from $52.00 to $62.00 and gave the company an “outperform” rating in a research report on Wednesday, September 9th. Guggenheim increased their target price on shares of Pharvaris from $40.00 to $44.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. Finally, Oppenheimer reissued an “outperform” rating and set a $75.00 target price on shares of Pharvaris in a research report on Tuesday, September 8th. Thirteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $59.87.

Institutional Investors Weigh In On Pharvaris

Several institutional investors and hedge funds have recently bought and sold shares of the business. venBio Partners LLC acquired a new stake in Pharvaris during the second quarter valued at approximately $160,569,809. 5AM Venture Management LLC acquired a new position in shares of Pharvaris in the 2nd quarter worth approximately $27,581,008. BlackRock Inc. acquired a new position in shares of Pharvaris in the 2nd quarter worth approximately $26,677,000. Elmind Capital LP bought a new position in shares of Pharvaris during the 2nd quarter worth approximately $18,180,435. Finally, Seven Fleet Capital Management LP lifted its position in shares of Pharvaris by 144.6% during the 2nd quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company’s stock worth $26,782,000 after buying an additional 457,804 shares during the period.

About Pharvaris

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.